Connection
Gregory Schwartz to Diabetic Angiopathies
This is a "connection" page, showing publications Gregory Schwartz has written about Diabetic Angiopathies.
|
|
Connection Strength |
|
![](https://profiles.ucdenver.edu/Framework/Images/connection_left.gif) |
|
![](https://profiles.ucdenver.edu/Framework/Images/connection_right.gif) |
|
1.108 |
|
|
|
-
Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
Score: 0.576
-
Schrieks IC, Nozza A, St?hli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Ryd?n L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care. 2018 08; 41(8):1792-1800.
Score: 0.532
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|